Stock of Avalo Therapeutics, Inc. (AVTX) is rising about 38 percent in Wednesday morning trading after the company priced an offering of 250 million shares of common stock and pre-funded warrants at a combined price of $1.50 per share. This article is part of our premium content offering.Subscribe with a RTTNews subscription. The company's shares are currently trading at $22.42 on the Nasdaq, up 38.13 percent. The stock opened at $22.80 and has climbed as high as $23.71 so far in today's session. Over the p ...

Cytokinetics (NASDAQ: CYTK) is a biopharmaceutical company focused on muscle biology. It develops treatments for diseases that involve muscle weakness and fatigue. A key product for Cytokinetics is MYQORZO, a drug designed to treat adults with a heart condition known as symptomatic obstructive hypertrophic cardiomyopathy (HCM). On May 5, 2026, Cytokinetics reported its first-quarter financial results. The company posted a loss of $1.67 per share, which met analyst expectations. As highlighted by Zacks, this ...

公司融资活动 - 公司以每股5.00美元的价格发行了800万股普通股 [2] - 公司同时以每股4.999美元的价格发行了可购买额外800万股股票的预融资认股权证 [3] - 此次发行预计总收益为8000万美元 用于支持Eversense 365系统的持续商业发布和管线产品的持续开发 [3] - 承销商被授予30天期权 可额外购买最多240万股股票 [3] - 此次发行预计将于5月4日完成 [4] 股价市场反应 - 公司股价在周五早盘交易中出现显著抛售 [4] - 根据数据 周五发布时公司股价下跌22.54%至5.12美元 [5]